Unrestricted public coverage is needed for smoking cessation pharmacotherapies

CMAJ. 2024 Jan 21;196(2):E53-E55. doi: 10.1503/cmaj.231333.

Authors

Robert A Kleinman¹, Peter Selby²

Affiliations

¹ Centre for Addiction and Mental Health (Kleinman, Selby); Department of Psychiatry (Kleinman), and of Family and Community Medicine (Selby), University of Toronto, Toronto, Ont. robert.kleinman@camh.ca.
² Centre for Addiction and Mental Health (Kleinman, Selby); Department of Psychiatry (Kleinman), and of Family and Community Medicine (Selby), University of Toronto, Toronto, Ont.

No abstract available

MeSH terms

Humans
Smoking Cessation*

Grants and funding

R25 DA033211/DA/NIDA NIH HHS/United States